leadf
logo-loader
viewBiocept Inc

Biocept expands uses for its Target Selector liquid biopsy tech, expands coronavirus testing

Biocept Inc (NASDAQ: BIOC) CEO Mike Nall tells Proactive the molecular diagnostics company, is expanding uses for its flagship liquid biopsy Target Selector technology which detects cancer biomarkers.

What's more, Nall says, is the California-based company is expanding its coronavirus molecular diagnostic test to its current client base, with a current capacity of 100 tests per day, with the ability to ramp its capacity to 400 tests per day.

Quick facts: Biocept Inc

Price: 4.49 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $60.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: Biocept receives CE-IVD Mark for Target Selector test kit...

Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving their CE-IVD Mark that allows Biocept to commercialize its kits throughout the European Union and other CE...

on 5/5/20

2 min read